Search

Your search keyword '"Atayar E"' showing total 4 results
Start Over Author "Atayar E" Topic nephrotic syndrome
4 results on '"Atayar E"'

1. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation.

Author

Atmaca M, Gülhan B, Atayar E, Bayazıt AK, Candan C, Arıcı M, Topaloğlu R, and Özaltın F

Subjects
Adolescent, Adult, Asymptomatic Diseases, Child, Child, Preschool, Dietary Supplements, Early Diagnosis, Female, Follow-Up Studies, Genetic Markers, Humans, Male, Mutation, Nephrotic Syndrome complications, Nephrotic Syndrome diagnosis, Nephrotic Syndrome genetics, Proteinuria diagnosis, Proteinuria etiology, Ubiquinone therapeutic use, Young Adult, Nephrotic Syndrome drug therapy, Protein Kinases genetics, Ubiquinone analogs & derivatives, Vitamins therapeutic use
Abstract

Atmaca M, Gülhan B, Atayar E, Karabay Bayazıt A, Candan C, Arıcı M, Topaloğlu R, Özaltın F. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation. Turk J Pediatr 2019; 61: 657-663. ADCK4-related glomerulopathy is a recently recognized clinical entity associated with insidious onset in young children and a high potential to progress to chronic kidney disease in adolescents. Early initiation of exogenous coenzyme Q10 (CoQ10) supplementation in the asymptomatic period could be protective on renal functions. In the present study, we aimed to investigate long-term follow-up of patients that we have diagnosed during the asymptomatic period and in whom we started CoQ10 treatment. We analyzed long-term effects of CoQ10 on proteinuria and estimated glomerular filtration rate (eGFR) in this patient population. A total of 8 patients (4 female, 4 male) from 6 different families were included. The mean age at diagnosis and at last visit were 16.8±11.2 years and 20.7±11.7 years, respectively. None of the patients had extrarenal system involvement. At the time of initiation of treatment; median eGFR was 107.8 ml/min/1.73 m2, median proteinuria was 1008 mg/m2/day. After a median follow-up period of 25.3±5.8 months, median proteinuria decreased to 318.5 mg/m2/day (p=0.03) and median eGFR remained stable at 99.6 ml/min/1.73 m2 (p=0.21). Coenzyme Q10 treatment is effective for reducing proteinuria and seems to be renoprotective.

Published
2019
Full Text
View/download PDF

2. Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: Answers.

Author

Saygili S, Canpolat N, Sever L, Caliskan S, Atayar E, and Ozaltin F

Subjects
Adrenal Glands pathology, Adrenal Insufficiency blood, Adrenal Insufficiency etiology, Blood Glucose analysis, Fatal Outcome, Female, Gluconeogenesis, Glucose administration & dosage, Glucose metabolism, Humans, Hydrocortisone blood, Hypoglycemia etiology, Hypoglycemia therapy, Infant, Kidney pathology, Nephrotic Syndrome blood, Parenteral Nutrition, Adrenal Insufficiency diagnosis, Hypoglycemia diagnosis, Nephrotic Syndrome therapy, Renal Dialysis adverse effects, Sepsis complications
Published
2019
Full Text
View/download PDF

3. Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: Questions.

Author

Saygili S, Canpolat N, Sever L, Caliskan S, Atayar E, and Ozaltin F

Subjects
Adrenal Insufficiency blood, Adrenal Insufficiency complications, Blood Glucose analysis, Diagnosis, Differential, Fatal Outcome, Female, Glucose administration & dosage, Humans, Hydrocortisone blood, Hypoglycemia etiology, Hypoglycemia therapy, Infant, Nephrotic Syndrome blood, Parenteral Nutrition, Adrenal Insufficiency diagnosis, Hypoglycemia diagnosis, Nephrotic Syndrome therapy, Renal Dialysis adverse effects
Published
2019
Full Text
View/download PDF

4. children with Alport syndrome

Author

Ozdemir, G, Gulhan, B, Atayar, E, Saygili, S, Soylemezoglu, O, Ozcakar, ZB, Eroglu, FK, Candan, C, Demir, BK, Soylu, A, Yuksel, S, Alpay, H, Agbas, A, Duzova, A, Hayran, M, Ozaltin, F, and Topaloglu, R

Subjects
Nephrotic syndrome, Cyclosporin A, Alport syndrome, COL4A mutations, Focal segmental glomerulosclerosis
Abstract

Background Alport syndrome (AS) is an inherited glomerular disease caused by mutations in COL4A3, COL4A4, or COL4A5. Associations between clinical manifestations and genotype are not yet well defined. Our study aimed to define clinical and genetic characteristics, establish genotype-phenotype correlations, and determine prognosis of AS in children. Methods A total of 87 children with AS from 10 pediatric nephrology centers, whom had genetic analyses performed at the Hacettepe University Nephrogenetics Laboratory between February 2017 and February 2019, were included. Data regarding demographics, family history, clinical and laboratory characteristics, histopathological and genetic test results, treatments, and yearly follow-up results were retrospectively analyzed. Results Of 87 patients, 16% presented with nephrotic syndrome. In patients with nephrotic syndrome, kidney biopsy findings showed focal segmental glomerulosclerosis (FSGS) in 79%, and COL4A3 mutations were the leading genetic abnormality (50%). Twenty-four percent of all patients progressed to chronic kidney disease (CKD). The rate of progression to CKD and the decline in the glomerular filtration rate of the patients with COL4A3 mutation were higher than other mutation groups (p < 0.001 and p = 0.04, respectively). In kidney survival analysis, nephrotic syndrome presentation, histopathology of FSGS, COL4A3 mutations, and autosomal recessive inheritance were found as independent risk factors for earlier progression to CKD. Cyclosporin A treatment did not improve kidney survival. Conclusions We emphasize that genetic testing is important for patients suspected as having AS. Furthermore, COL4A mutations should be considered in patients with FSGS and steroid-resistant nephrotic syndrome. This approach will shed light on the prognosis of patients and help with definitive diagnosis, preventing unnecessary and potentially harmful medications. C1 [Ozdemir, Gulsah; Gulhan, Bora; Duzova, Ali; Ozaltin, Fatih; Topaloglu, Rezan] Hacettepe Univ, Fac Med, Div Pediat Nephrol, TR-06230 Ankara, Turkey. [Atayar, Emine; Ozaltin, Fatih] Hacettepe Univ, Fac Med, Div Pediat Nephrol, Nephrogenet Lab, Ankara, Turkey. [Saygili, Seha] Istanbul Univ Cerrahpasa, Fac Med, Div Pediat Nephrol, Istanbul, Turkey. [Soylemezoglu, Oguz] Gazi Univ, Fac Med, Div Pediat Nephrol, Ankara, Turkey. [Ozcakar, Zeynep Birsin] Ankara Univ, Fac Med, Div Pediat Nephrol, Ankara, Turkey. [Eroglu, Fehime Kara] Dr Sami Ulus Matern & Childrens Hlth Hosp, Div Pediat Nephrol, Ankara, Turkey. [Candan, Cengiz] Istanbul Medeniyet Univ, Goztepe Training & Res Hosp, Div Pediat Nephrol, Istanbul, Turkey. [Demir, Belde Kasap] Tepecik Training & Res Hosp, Div Pediat Nephrol, Izmir, Turkey. [Soylu, Alper] Dokuz Eylul Univ, Fac Med, Div Pediat Nephrol, Izmir, Turkey. [Yuksel, Selcuk] Pamukkale Univ, Fac Med, Div Pediat Nephrol, Denizli, Turkey. [Alpay, Harika] Marmara Univ, Fac Med, Div Pediat Nephrol, Istanbul, Turkey. [Agbas, Ayse] Haseki Training & Res Hosp, Div Pediat Nephrol, Istanbul, Turkey. [Hayran, Mutlu] Hacettepe Univ, Fac Med, Dept Prevent Oncol, Ankara, Turkey.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results